PS13

Long COVID

National Institute of Mental Health (NIMH)Small moleculePhase 1Active

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 89/ 100

Competitive context

31 Active assets in the Long COVID cohort.

Asset / Sponsor	Phase	Rating
Immulina Tm University of Mississippi Medical Center	Phase 3	BB
MELATONIN Duke University	Phase 2	B
Rapamycin Icahn School of Medicine at Mount Sinai	Phase 3	B
Paxlovid Kanecia Obie Zimmerman	Phase 2	B
RITONAVIR Kanecia Obie Zimmerman	Phase 2	B

View all 31 →

Same molecule, other indications

PS13 is also rated in:

multiple sclerosisDormant

CCC

Indicative ·

48 / 100

dementiaDormant

CC

Indicative ·

41 / 100

amyotrophic lateral sclerosisDormant

CC

Indicative ·

41 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.